Clinical Trial

Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics

Name: Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics — clinical trial record (NCT07758231)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TAP

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.

Trial Details

NCT Number	NCT07758231
Lead Sponsor	University of Wisconsin, Madison
Conditions	GLP-1, Alcohol
Enrollment	5 participants
Start Date	2026-10
Primary Completion	2027-03 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-11